Utilizing Autologous Multipotent Mesenchymal Stromal Cells and [beta]-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial

• Published in: BioMed research international Vol. 2016
• Main Authors: Sponer, Pavel, Filip, Stanislav, Kucera, Tomas, Brtkova, Jindra, Urban, Karel, Palicka, Vladimir, Koci, Zuzana, Syka, Michael, Bezrouk, Ales, Sykova, Eva
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01-01-2016; Hindawi Limited
• Subjects: Calcium phosphate; Calcium phosphates; Chemical industry; Defects; Heart attacks; Hospitals; Hydroxyapatite; Joint surgery; Medicine; Pancreatic beta cells; Patients; Stem cells; Surgery; Transplants & implants
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2016/2076061

The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous β-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or β-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P<0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of β-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P<0.05). Using autologous mesenchymal stromal cells combined with a β-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).